Abstract: The present disclosure includes peripheral partial agonists of one or more CB receptors, including modulation of CB1, both with and without CB2 selectivity. The compounds of the present disclosure may be useful in the treatment of diseases and disorders mediated by a CB-signaling pathway, including but not limited to pain, gastrointestinal disorders, metabolic disorders, and liver disorders, such as alcoholic steatohepatitis or nonalcoholic steatohepatitis (NASH).

Abstract: A fatty phase for the preparation of hair dyes, consisting of a semi-finished product containing the proportions of stearyl and cetyl alcohols suitable for the preparation of the dye. In relation to the prior art, the invention allows a semi-finished product for preparation of hair dyes to be obtained, consisting of a fatty phase with the ingredients already measured out and mixed, so as to be ready to be integrated, inside the mixer, with the remaining components (colorants, etc.) that make up the final formulation of the dye.

Abstract: A device for weighing the colorants used in the preparation of hair dyes, including a plurality of collecting bins (2) for the individual colorants, as well as an automatic system for automatically picking up the colorants from each bin, in quantities in accordance with the formulation of the dyes. Compared with the prior art methods of the field, the device of the invention offers the advantage of mechanising the operations of weighing and metering the colorants in the mixture, thus avoiding direct intervention by the operator.

Abstract: A fatty phase for the preparation of hair dyes, consisting of a semi-finished product containing the proportions of stearyl and cetyl alcohols suitable for the preparation of the dye. In relation to the prior art, the invention allows a semi-finished product for preparation of hair dyes to be obtained, consisting of a fatty phase with the ingredients already measured out and mixed, so as to be ready to be integrated, inside the mixer, with the remaining components (colorants, etc.) that make up the final formulation of the dye.

Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.

Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.